The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.
Han Sang KimChang Gon KimJung Yong HongIl-Hwan KimBeodeul KangSanghoon JungChan KimSang Joon ShinHye Jin ChoiJaekyung CheonHong Jae ChonHo Yeong LimPublished in: Therapeutic advances in medical oncology (2022)
The presence and size of liver tumors, liver function, and NLR are key factors determining the response to nivolumab in aHCC. These clinical factors should be considered when treating patients with advanced HCC with PD-1 blockade.
Keyphrases